Namakoola, I; Kasamba, I; Mayanja, BN; Kazooba, P; Lutaakome, J; Lyagoba, F; Kapaata, AA; Kaleebu, P; Munderi, P; CoLTART study team; (2016) From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults. BMC. DOI: https://doi.org/10.1186/s13104-016-2309-7

Downloaded from: http://researchonline.lshtm.ac.uk/4259122/

DOI: https://doi.org/10.1186/s13104-016-2309-7

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults

Ivan Namakoola1, Ivan Kasamba1,2, Billy N. Mayanja1*, Patrick Kazooba1, Joseph Lutaakome1, Fred Lyagoba1, Anne A. Kapaata1, Pontiano Kaleebu1,3, Paula Munderi1 and On behalf of the CoLTART study team

Abstract

Background: HIV care programs in resource-limited settings have hitherto concentrated on antiretroviral therapy (ART) access, but HIV drug resistance is emerging. In a cross-sectional study of HIV-positive adults on ART for ≥6 months enrolled into a prospective cohort in Uganda, plasma HIV RNA was measured and genotyped if ≥1000 copies/ml. Identified Drug resistance mutations (DRMs) were interpreted using the Stanford database, 2009 WHO list of DRMs and the IAS 2014 update on DRMs, and examined and tabulated by ART drug classes.

Findings: Between July 2013 and August 2014, 953 individuals were enrolled, 119 (12.5%) had HIV-RNA ≥1000 copies/ml and 110 were successfully genotyped; 74 (67.3%) were on first-line and 36 (32.7%) on second-line ART regimens. The predominant HIV-1 subtypes were D (34.5%), A (33.6%) and Recombinant forms (21.8%). The commonest clinically significant major resistance mutations associated with the highest levels of reduced susceptibility or virological response to the relevant Nucleoside Reverse Transcriptase Inhibitor (NRTI) were; the Non-thymidine analogue mutations (Non-TAMS) M184V—20.7% and K65R—8.0%; and the TAMs M41L and K70R (both 8.0%). The major Non-NRTI (NNRTI) mutations were K103N—19.0%, G190A—7.0% and Y181C—6.0%. A relatively nonpolymorphic accessory mutation A98G—12.0% was also common. Seven of the 36 patients on second line ART had major Protease Inhibitor (PI) associated DRMS including; V82A—7.0%, I54V, M46I and L33I (all 5.0%). Also common were the accessory PI mutations L10I—27%, L10V—12.0% and L10F—5.0% that either reduce PI susceptibility or increase the replication of viruses containing PI-resistance mutations. Of the 7 patients with major PI DRMs, five had high level resistance to ritonavir boosted Lopinavir and Atazanavir, with Darunavir as the only susceptible PI tested.

Conclusions: In resource-limited settings, HIV care programs that have previously concentrated on ART access, should now consider availing access to routine HIV viral load monitoring, targeted HIV drug resistance testing and availability of third-line ART regimens.

Keywords: Antiretroviral therapy, Drug resistance, Mutations, Third-line regimen
of which 13.5 million were in low- and middle-income countries [2]. In Uganda, 750,896 (50%) HIV infected people were receiving ART by December 2014 [3].

Despite the progress in the rapid ART scale up, HIV drug resistance profiling prior to starting ART, and routine virological monitoring and drug resistance testing are not yet standard HIV care in resource limited settings as is the case in the developed world [4]. The emergence of HIV drug resistance may limit the sustained benefits of ART in settings with limited laboratory monitoring and drug options. Drug resistance prevalence varies widely, at 2.8% in sub-Saharan Africa compared to 11.5% in North America, while in South Africa rising levels of acquired antiretroviral drug resistance and newly infected patients with resistant viruses have been reported [5, 6].

Although HIV care programs in resource limited settings have hitherto concentrated on expanding ART access, the emergency of HIV drug resistance is a challenge. We document the antiretroviral (ARV) drug resistance mutations and susceptibility patterns among Ugandan adults on ART. We also highlight the need for HIV care programs in resource limited settings to avail access to routine virological monitoring, access to targeted HIV drug resistance testing and alternative third line ART regimen drugs.

This was a cross-sectional study of HIV-positive adults (18 years and above) at enrolment into a prospective clinical cohort established to study the complications of long-term ART (CoLTART). Individuals on ART for 6 months or more were recruited from two ART cohorts; the Entebbe site of the former Development of Antiretroviral Therapy in Africa (DART) Trial cohort established in 2003 [7], and the former Rural Clinical Cohort in south western Uganda where ART was introduced in 2004 [8]. ART history was obtained from the former ART cohorts and included; dates of ART initiation and switches, ART regimen types and duration on ART. The three ART regimen types were; Triple nucleoside (3 NRTIs), 2 NRTIs with a NNRTI, and a PI-based regimen. Duration on ART was grouped into below 5 years, 5–9 years, and above 9 years. Drug resistance mutations to one antiretroviral class only (either NRTI, NNRTI or PI), two classes only (either NRTI and NNRTI, PI and NRTI, or PI and NNRTI) or three antiretroviral classes (NRTI and 1 NNRTI and PI) were tabulated. For participants with a major PI DRM, we showed the resistance levels to each antiretroviral drug.

Findings
Out of the 953 individuals on ART for 6 or more months, 119 (12.5%) had a viral load \( \geq 1000 \) copies/mL or higher. The five samples that did not amplify and the 4 with insufficient quantities were excluded from this analysis. Of the 110 individuals whose samples were sequenced for drug resistance testing, 73 (66.4%) were females, 95 (86.4%) were aged 35 years and above, 89 (80.9%) had been on ART for 9 or more years, with 74 (67.3%) on first and 36 (32.7%) on second-line ART regimens at enrolment.
Sixty-five (59.1%) had CD4 cell counts of 350 cells/ml or less and 67 (60.9%) had HIV RNA of 10,000 copies/ml or more. The predominant HIV-1 subtypes were D (34.5%), A (33.6%) and Recombinant forms (21.8%) (Table 1). Of the 110 individuals with drug resistance testing results, 8 (7.3%) had no detectable drug resistance mutations (DRMs) while 102 (92.7%) had at least one detectable DRMs, distributed as follows: DRMs to any NRTI—92 (83.6%), to any NNRTIs—77 (70.0%) and to any PIs—33 (30.0%). DRMs by ART regimen line were: triple nucleoside—39 (35.5%), 2NRTI with an NNRTI—77 (70.0%) and second-line PI based regimen—33 (30.0%). Twenty-two participants (20.0%) had DRMs to one ARV class only (NRTI—14, NNRTI—7 and PI—1), 60 (54.5%) participants had dual-class DRMs (NRTI + NNRTI—48, PI + NRTI—10 and PI + NNRTI—2, while 20 (18.2%) had triple class DRMs (Table 2).

In our cohort, the commonest clinically significant major NRTI resistance mutations associated with highest levels of reduced susceptibility or virological response were the Non-thymidine analogue mutations (Non-TAMs): M184V—20.7% and K65R—8.0%, while M41L and K70R (both 8.0%) were the commonest TAMs. The commonest major NNRTI resistance mutations known to reduce susceptibility or virological response to NNRTIs were: K103N—19.0%, G190A—7.0% and Y181C—6.0%. A relatively nonpolymorphic accessory mutation A98G—12.0% was also common. Of the 33 identified PI resistance mutations, 7 were major mutations and 26 minor mutations. The most common major PI-resistance mutations associated with the highest levels of phenotypic resistance were: V82A—7.0% and I54V, M46I, L33I (all 5.0%). The identified accessory PI resistance mutations that either reduce PI susceptibility or increase the replication of viruses containing PI-resistance mutations included: L10I—27.0%, L10V—12.0% and L10F—5.0% (Table 2).

Of the 7 patients with major PI DRMs, high level resistance to Indinavir (IDV), Fosamprenavir (FPV), Lopinavir (LPV) and Nelfinavir (NFV)—to each was found among 4 patients. Intermediate level drug resistance to Saquinavir (SQV) was found among 4 patients, Tipranavir (TPV) and IDV among 3 patients. The HIV among six of the 7 patients with major PI mutations were susceptible to Darunavir with one expressing low level resistance to this drug, and two expressing susceptibility to Tipranavir (Table 3).

**Conclusions**

We found that nearly half of our patients with virological failure had resistance to both NRTIs and NNRTIs, about a fifth had resistance to the three classes of ARVs commonly used in Uganda while a small proportion had no Drug Resistance Mutations (DRMs). NRTIs have fewer side effects and toxicity than NNRTIs, but drug resistance could diminish their efficacy. As expected in Africa, the predominant NRTI mutation observed was M184V [13]. Type 1 TAM M41L causes higher levels of phenotypic and clinical resistance to thymidine analogues and cross resistance to Abacavir, Tenofovir and Didanosine than Type 11 K70R. The M184V and K65R DRMs might be

**Table 1** Characteristics of participants with HIV viral loads ≥1000 copies/ml at enrolment by ART regimen line

| Characteristic | All participants n (%) | ART regimen line n (%) |  |
|---------------|------------------------|------------------------|---|
|               | First line ART n (%)   | Second line ART n (%)  |   |
| All (n, row %)| 110                    | 74 (67.3)              | 36 (32.7) |
| Study site    |                        |                        |   |
| Entebbe       | 90 (81.8)              | 65 (87.8)              | 25 (69.4) |
| Kyamulibwa    | 20 (18.2)              | 9 (12.2)               | 11 (30.6) |
| Sex           |                        |                        |   |
| Females       | 73 (66.4)              | 53 (71.6)              | 20 (55.6) |
| Males         | 37 (33.6)              | 21 (28.4)              | 16 (44.4) |
| Age, years    |                        |                        |   |
| 18–34         | 15 (13.6)              | 6 (8.1)                | 9 (25.0) |
| 35–49         | 72 (65.5)              | 50 (67.6)              | 22 (61.1) |
| ≥50           | 23 (20.9)              | 18 (24.3)              | 5 (13.9) |
| Body Mass Index [kg/m²]³ |                   |                        |   |
| <18.5         | 15 (13.6)              | 7 (9.5)                | 8 (22.2) |
| 18.5–24.9     | 63 (57.3)              | 44 (59.5)              | 19 (52.8) |
| 25.0–29.9     | 20 (18.2)              | 14 (18.9)              | 6 (16.7) |
| ≥30           | 11 (10.0)              | 8 (10.8)               | 3 (8.3) |
| HIV subtype   |                        |                        |   |
| A             | 37 (33.6)              | 25 (33.8)              | 12 (33.3) |
| B             | 5 (4.5)                | 3 (4.1)                | 2 (5.6) |
| C             | 6 (5.5)                | 5 (6.8)                | 1 (2.8) |
| D             | 38 (34.5)              | 22 (29.7)              | 16 (44.4) |
| CRF01_AE      | 24 (21.8)              | 19 (25.7)              | 5 (13.9) |
| CD4 cell counts at enrolment—cells/ml⁶ |                   |                        |   |
| ≤350          | 65 (59.1)              | 41 (55.4)              | 24 (66.7) |
| 351–500       | 26 (23.6)              | 22 (29.7)              | 4 (11.1) |
| 501+          | 11 (10.0)              | 5 (6.8)                | 6 (16.7) |
| Total duration on ART, years⁵ |                   |                        |   |
| 0–<5          | 15 (13.6)              | 9 (12.2)               | 6 (16.7) |
| 5–<9          | 6 (5.5)                | 2 (2.7)                | 4 (11.1) |
| 9+            | 89 (80.9)              | 63 (85.1)              | 26 (72.2) |
| Duration on current ART regimen, years⁵ |                   |                        |   |
| <5            | 17 (15.5)              | 9 (12.2)               | 8 (22.2) |
| 5–<9          | 17 (15.5)              | 2 (2.7)                | 15 (41.7) |
| 9+            | 63 (57.3)              | 63 (85.1)              | 0 (0.0) |
| Viral loads (copies/ml) |                   |                        |   |
| 1000–9999    | 43 (39.1)              | 29 (39.2)              | 14 (38.9) |
| 10,000+      | 67 (60.9)              | 45 (60.8)              | 22 (61.1) |

Missing variable data: a = 1 patient on first line ART, b = 8 patients (6 on first and 2 on second line ART), c = 13 patients on second line ART
due to the Tenofovir and Lamivudine ART backbone and the triple nucleoside regimen of Abacavir-Zidovudine-Lamivudine that most of our patients were initiated on. Triple nucleoside first-line ART regimens have since been discontinued as they are virologically inferior to a regimen containing Efavirenz (NNRTI) plus two or three NRTIs [14]. The NNRTI mutations observed included K103N, G190A and Y181C which cause high level resistance to Nevirapine and variable resistance to Efavirenz [15]. The observed PI resistance mutations (V82A, V82F, V82S, M46L, M46L and I54V) are clinically significant because they are associated with highest levels of phenotypic resistance and/or strongest evidence for interfering with successful PI therapy. Among the seven patients, these mutations conferred high level resistance to ritonavir boosted Lopinavir and Atazanavir, which are the readily available PIs for second-line ART regimens in our setting. Darunavir, the only susceptible PI tested is still expensive and unavailable in public ART centers in Uganda where PIs are reserved for second-line ART regimens. The emergence of HIV drug resistance is inevitable, owing to the high replication and mutation rates of HIV and ART being a life-long treatment. Therefore, as more people are switched to second-line ART, cases of second-line drug failure will increase and necessitate access to third-line or salvage regimens. In Uganda, routine viral load monitoring is not yet standard care, making early identification of treatment failures to prevent transmission of DRMs impossible. Uganda is yet to recommend HIV genotyping prior to ART initiation, therefore diagnosing transmitted

Table 2 Drug resistance mutations (DRMs) of participants tested for drug resistance among those with HIV viral loads ≥1000 copies/ml at enrolment, by ARV class

| Drug resistance mutation(s) | Proportion with amplified drug resistance tests, n (%) | Proportion with major PI mutations, n (%) | Most common mutations² |
|-----------------------------|----------------------------------------------------|------------------------------------------|-------------------------|
| All                         | 110                                                | 7 (6.4)                                  | Non-TAMs: M184V (20.7%), K65R (8.0%) TAMs: M41L (8.0%), K70R (8.0%) |
| No mutation detected        | 8 (7.3)                                            | 0 (0.0)                                  | K103N (19.0%), G190A (7.0%), Y181C (6.0%) |
| Any NRTI                    | 102 (92.7)                                         | 7 (6.9)                                  | Major: V82A (7.0%) and I54V, M46I, L33I (all 5.0%) Accessory: L10I (27.0%), L10V (12.0%), L10F (5.0%) |
| Any NNRTI                   | 92 (83.6)                                          | 6 (6.5)                                  |                                      |
| Any PI³                     | 77 (70.0)                                          | 4 (5.2)                                  |                                      |

Mutation to 1 ARV class only (n = 22)

| ARV class   | Proportion with amplified drug resistance tests, n (%) | Proportion with major PI mutations, n (%) | Most common mutations² |
|-------------|------------------------------------------------------|------------------------------------------|-------------------------|
| NRTI        | 14 (12.7)                                            | 0 (0.0)                                  | Non-TAMs: M184V (20.7%), K65R (8.0%) TAMs: M41L (8.0%), K70R (8.0%) |
| NNRTI       | 7 (6.4)                                              | 0 (0.0)                                  | K103N (19.0%), G190A (7.0%), Y181C (6.0%) |
| PI          | 1 (0.9)                                              | 0 (0.0)                                  | Major: V82A (7.0%) and I54V, M46I, L33I (all 5.0%) Accessory: L10I (27.0%), L10V (12.0%), L10F (5.0%) |

Mutation to 2 ARV classes only (n = 60)

| ARV class   | Proportion with amplified drug resistance tests, n (%) | Proportion with major PI mutations, n (%) | Most common mutations² |
|-------------|------------------------------------------------------|------------------------------------------|-------------------------|
| NRTI + NNRTI| 48 (43.6)                                            | 0 (0.0)                                  | Non-TAMs: M184V (20.7%), K65R (8.0%) TAMs: M41L (8.0%), K70R (8.0%) |
| PI + NRTI   | 10 (9.1)                                             | 3 (30.0)                                 | K103N (19.0%), G190A (7.0%), Y181C (6.0%) |
| PI + NNRTI  | 2 (1.8)                                              | 1 (50.0)                                 | Major: V82A (7.0%) and I54V, M46I, L33I (all 5.0%) Accessory: L10I (27.0%), L10V (12.0%), L10F (5.0%) |

Mutation to 3 ARV classes (n = 20)⁴

| HIV subtype | Proportion with amplified drug resistance tests, n (%) | Proportion with major PI mutations, n (%) | Most common mutations² |
|-------------|------------------------------------------------------|------------------------------------------|-------------------------|
| A           | 37 (33.6)                                            | 3 (8.1)                                  | V82A/V, IS4/V, M46/I, K43/T, L10F, L89/V, L24I |
| B           | 5 (4.5)                                              | 0 (0.0)                                  |                              |
| C           | 6 (5.5)                                              | 0 (0.0)                                  |                              |
| D           | 38 (34.5)                                            | 4 (10.5)                                 | V82A/V/F, IS4/V, M46/I, L33F, L10I, L10F, L24I, K20I, A71T, Q58E, I47V |
| CRF01_AE    | 24 (21.8)                                            | 0 (0.0)                                  |                              |

TAMs thymidine analogue mutations

¹ These are row percentages of participants with major PI mutations in each category with amplified drug resistance tests
² Denominator is all mutations to NRTI (n = 352), NNRTI (n = 144) or PI (n = 59)
³ PI DRMs include 7 with a major and 26 with only minor PI DRMs
⁴ Only major PI mutations are shown for HIV subtypes
Table 3: Drug resistance mutations and loss of protease inhibitor (PI) drug options among patients with any major PI mutation

| Patient ID | Sex | Age (years) | Viral load (copies/ml) | CD4 (cells/mm$^3$) | Duration on ART (years) | Duration on second line ART (years) | HIV-1 sub-type | Identified drug resistance mutations | Level of PI resistance |
|------------|-----|-------------|------------------------|-------------------|------------------------|-------------------------------------|----------------|------------------------------------|----------------------------|
| CoL-1      | M   | 57          | 339,081                | 165               | 9.4                    | 3.6                                 | A             | M184V, K65R, A62V V82S, I54V, M46I, L24I, L10F | ATV, FPV, IDV, LPV, SQV, TPV, DRV |
| CoL-2      | F   | 58          | 3886                   | 620               | 9.3                    | 6.2                                 | A             | M184V V82A, I54V, M46I, L89I, L10F | ATV, FPV, IDV, LPV, NSFV, SQV, TPV, DRV |
| CoL-3      | M   | 38          | 13,560                 | 130               | 9.4                    | 6.6                                 | D             | A98G, L100I, K103M M41L, T215Y, L74V | ATV, FPV, IDV, SQV, LPV, NFV, DRV |
| CoL-4      | M   | 34          | 221,251                | 130               | 9.0                    | 6.7                                 | D             | M184V, M41L, T215Y M41L, T215Y | ATV, FPV, IDV, LPV, NSFV, SQV, TPV, DRV |
| CoL-5      | M   | 69          | 14,127                 | 287               | 9.2                    | 7.2                                 | A             | K103N V82A | ATV, LPV, SQV, DRV, TPV |
| CoL-6      | F   | 39          | 68,537                 | 9.8               | 7.3                    | D                                   | K103N, L100I, Y181F M184L, L74V, M41L, T215A | ATV, LPV, SQV, DRV, TPV |
| CoL-7      | F   | 40          | 98,489                 | 97                | 9.0                    | 7.8                                 | D             | G190A, Y181C, K101E M41L, L210W, K219E, T215C | ATV, LPV, SQV, DRV, TPV |

F Female, M Male, PI Protease inhibitor, NRTI Nucleoside Reverse Transcriptase Inhibitor, NNRTI Non-Nucleoside Reverse Transcriptase Inhibitor, ATV Atazanavir, DRV Darunavir, FPV Fosamprenavir, IDV Indinavir, LPV Lopinavir, NFV Nelfinavir, SQV Saquinavir, TPV Tipranavir
HIV drug resistance is impossible. The strength of our study is the long duration on ART among our participants. A source of selection bias might be that some patients with virological failure might have died before enrolment. We also had limited information on confounders like adherence so our findings may not be generalizable. In conclusion, HIV drug resistance is a major challenge for HIV care programs in resource limited settings that have hitherto concentrated on increasing ART access. Therefore, ART programs in these settings should avail routine HIV viral load monitoring for prompt detection of virological failures, targeted HIV drug resistance testing to detect HIV drug resistance among ART failure as well as access to third-line ARV drugs like Darunavir.

Abbreviations
HIV: human immunodeficiency virus; ART: antiretroviral therapy; RNA: ribonucleic acid; DRM: drug resistance mutation; WHO: World Health Organisation, IAS: International AIDS Society; NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: non nucleoside reverse transcriptase inhibitors; PI: protease inhibitors; AIDS: acquired immune deficiency syndrome; ARV: antiretroviral; CoLTART: Complications of Long-Term Antiretroviral Therapy; DART: development of antiretroviral therapy in Africa; RIP: recombinant identification program; TDR: transmitted drug resistance; IAS: International AIDS Society; CPR: calibrated population resistance tool.

Authors’ contributions
BNM, PM, PoK conceived and designed the study; IN, BNM, PaK, JL, FL, AAK participated in data collection; FL, AAK, PoK conducted the laboratory analyses; IN, BNM, JL, drafted the initial manuscript; IK compiled and analysed data; IN, IK, BNM, JL, FL, AAK, PoK, PM interpreted the analysis; all authors contributed to manuscript revisions. All authors read and approved the final manuscript.

Author details
1 MRC/UVRI Uganda Research Unit on AIDS, PO. Box 49, Entebbe, Uganda.
2 AMRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. 3 Department of Clinical Research, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.

Acknowledgements
We acknowledge the contribution of CoLTART study participants, the CoLTART study team, and staff of the Clinical Diagnostic Laboratory Services, Basic Science and Statistics section.

The CoLTART study teamKyamulikwa study site Billy N. Mayanja, Judith Nalwadda, Gladys Nakibuuka, Harriet Namugenyi, Patrick Kazooba, Rosemary Lugueba. Entebbe study site Annet Mugisha, Apophia Terekha, Apulu Kalyebara, Arthur Namara, Diana Nakitto, Deus Wangi, Fred Nume, George Ssemwanga, Gertrude Nabulime, Gladys Nassuna, Gloria Lubega, Ivan Namakoolaa, Joseph Lutaakome, Lillian Generous, Lydia Matama, Rosemary Massa, Salome Tino, William Nakahima. Basic Science Virology Anne A. Kapataa, Brian Magamboa, Chris Parya, Frederick Lyagoba, Jamirah Nazziora, Maria Nannyongo. Clinical Diagnostic Laboratory Services Edward Muhingwa, Faith Mwalaluga, Florence Kabajuma, Hope Graia Nakazdbwe, Jackson Were, Joan Bwandinga, Juliet Bukenga, Member Zephyrin Kamushaaga, Peter Hughes, Peter Nkurunziza, Priscilla Agatha Balungi, Simon Mukusa, Sureyah Nassibwma, Tobias Vudrko, William Senyonga, Willyfyred Occhla. Statistics Annet Nakimbuge, Cathe-rine Nampewo, Doreen Nabumaa, Erima Naphtali, Grace Barigye, Irene Nakamanya, Ivan Kasamba, Jonathan Levin, Joseph Kahwa, Joy Namutebi Matovu, Lillian Namayirira, Ruth Namulindwa Lugueba, Sandra Nabalayo, Solomon Kaddu. Principal Investigator Paula Mundiener.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
Data will not be shared publicly due to the data sharing policy of the MRC/UVRI Uganda Research Unit on AIDS, which requires a prior data sharing agreement. However, a full Data set on the CoLTART study containing the data supporting the study findings in this report can be obtained from the Director, by email to: mrc@mcuganda.org or the corresponding author.

Ethics approval and consent to participate
The study was approved by the Research and Ethics Committee of the Uganda Virus Research Institute, and the Uganda National Council for Science and Technology. Participants gave informed signed (or witnessed thumbprinted) written consent to participate in the study and confidentiality was ensured throughout the study.

Funding
This research was jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement.

Received: 19 May 2016 Accepted: 1 December 2016
Published online: 23 December 2016

References
1. Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2013;18(1):115.
2. WHO. HIV/AIDS: Media centre. 2015: http://www.who.int/mediacentre/ factsheets/fs360/en/. Accessed 24 Sept 2015.
3. UNAIDS, The HIV and AIDS Uganda Country Progress Report. 2014. http://www.unaids.org/sites/default/files/country/documents/UGA_narrative_report_2015.pdf. Accessed 6 Oct 2015.
4. Kumarasamy N, Krishnan S. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings. Curr Open HIV AIDS. 2013;8(6):586–90.
5. Barth RE, et al. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10(3):153–66.
6. Ali A, et al. Molecular basis for drug resistance in HIV-1 proteases. Viruses. 2010;2(11):2509–35.
7. Mugyenyi P, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375(9709):123–31.
8. Morgan D, et al. An HIV-1 natural history cohort and survival times in rural Uganda. AIDS. 1997;11(5):633–40.
9. Hall T. BioEdit Biological sequence alignment Editor for Windows 95/98/NT/2000/XP/7; Copyright © 1997–2013 Tom Hall, Ibis Biosciences, Carlsbad, CA 92008. http://www.mbio.ncsu.edu/BioEdit/bioedit.html. Accessed 12 Sept 2015.
10. Gouy M, Guindon S, Gascuel O. SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol Biol Evol. 2010;27(2):221–4.
11. BioAfrica and R. Institute, HIV Bioinformatics. REGA HIV-1 & 2 Automated Subtyping Tool (Version 2.0). http://www.bioafrica.net/rega-genotype/html/subtypingvhv.html. Accessed 14 Sept 2015.
12. LANL, Los Alamos National Laboratory. HIV sequence database. Recombinant Identification Program (RIP). http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html. Accessed 20 May 2015.
13. Ssemwanga D, et al. Update on HIV-1 acquired and transmitted drug resistance in Africa. AIDS reviews. 2014;17(1):3–20.
14. Gulick RM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850–61.
15. Tambuyzer L, et al. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir Ther. 2009;14(1):103–9.